Update in Osteoporosis: Disclosures. Topics
|
|
- Loren Ashlynn Murphy
- 5 years ago
- Views:
Transcription
1 Update in Osteoporosis: 21 Michael Maricic, M.D. Catalina Pointe Rheumatogy Clinical Associate Professor of Medicine University of Arizona Disclosures Speakers Bureau, Consultant or Clinical Research Grant Support Merck Proctor and Gamble Aventis Lilly Novartis Amgen Roche Glaxo-Smith-Kline Topics Are vertebroplasty/kyphoplasty safe and effective Who should receive them Is generic alendronate as safe and effective as Fosamax? ONJ and Subtrochanteric femoral fractures with bisphosphonates Should patients on bisphosphonates for 5 years or more be given a drug holiday?
2 Topics Is it safe to use bisphosphonates or rpth with abnormal renal function? New Guidelines and Treatments for Glucocorticoidinduced osteoporosis? Where will denosumab fit into the therapeutic paradigm? Emerging therapies for osteoporosis? Are vertebroplasty/kyphoplasty safe and effective Original Article A Randomized Trial of Vertebroplasty for Painful Osteoporotic Vertebral Fractures Rachelle Buchbinder, Ph.D., Richard H. Osborne, Ph.D., Peter R. Ebeling, M.D., John D. Wark, Ph.D., Peter Mitchell, M.Med., Chris Wriedt, M.B., B.S., Stephen Graves, D. Phil., Margaret P. Staples, Ph.D., and Bridie Murphy, B.Sc. N Engl J Med Volume 361(6):5 August 6, 29
3 Scores on Measures of Overall Pain, Pain at Night and at Rest, Quality of Life Questionnaire Assessment of Quality of Life, and Disability Questionnaire Buchbinder R et al. N Engl J Med 29;361: Original Article A Randomized Trial of Vertebroplasty for Osteoporotic Spinal Fractures David F. Kallmes, M.D., Bryan A. Comstock, M.S., Patrick J. Heagerty, Ph.D., Judith A. Turner, Ph.D., David J. Wilson, F.R.C.R., Terry H. Diamond, F.R.A.C.P., Richard Edwards, F.R.C.R., Leigh A. Gray, M.S., Lydia Stout, B.S., Sara Owen, M.Sc., William Hollingworth, Ph.D., Basavaraj Ghdoke, M.D., Deborah J. Annesley-Williams, F.R.C.R., Stuart H. Ralston, F.R.C.P., and Jeffrey G. Jarvik, M.D., M.P.H. N Engl J Med Volume 361(6): August 6, 29 Secondary Outcome Measures at 1 Month (Intention-to-Treat Analyses) Kallmes DF et al. N Engl J Med 29;361:
4 Scores on Measures of Disability and Pain over a 3-Month Period Kallmes DF et al. N Engl J Med 29;361: Are vertebroplasty/kyphoplasty safe and effective Who should receive them? Which is more effective / safe? Patient selection Timing after fracture Does severity or number of fractures influence outcome? What about Generic Alendronate? Apotex, Inc. Barr Pharmaceuticals, Inc. Cobalt Laboratories, Inc. Dr. Reddy's Laboratories, Ltd. Mylan Pharmaceuticals, Inc. Barr Pharmaceuticals, Inc. Teva Pharmaceuticals Watson Laboratories, Inc.
5 Requirements for Generic Drugs To gain FDA approval, a generic drug must: Contain the same active ingredients as the innovator drug (inactive ingredients may vary) Be identical in strength, dosage, and route of administration Have the same use indications Be bioequivalent Generic Alendronate: Concerns While drugs must be bioequivalent, the FDA allows a variation of 2% of bioavailability. This is a range from 8% - 125% AUC, where there is considered to be no statistically significant difference. Fosamax vs Generic Alendronate 186 post menopausal women T score < months prior Bisphosphonate therapy Treatment 1. Brand Fosamax 7 mg/wk 2. Generic Alendronate 7 mg/wk 3. Actonel 35 mg/wk Ringe J. Rheumatol Int. 29 May 9 Ringe JD. Rheumatol Int. 29 May 9.
6 L/S Spine BMD Change Ringe J. Rheumatol Int. 29 May 9 Ringe JD. Rheumatol Int. 29 May 9. Hip BMD Change Ringe J. Rheumatol Int. 29 May 9 Ringe JD. Rheumatol Int. 29 May Month % GI Side Effects 32% 15% 9% Ringe J. Rheumatol Int. 29 May 9 Ringe JD. Rheumatol Int. 29 May 9.
7 What Should Clinicians do About Generic Alendronate? Use only in patients who are likely to be compliant with weekly bisphosphonates Consider other alternatives in high risk patients Closely monitor response with BMD or biochemical markers Is it safe to use bisphosphonates with abnormal renal function? Zoledronic Acid: Renal Safety in HORIZON-PFT
8 Zoledronic Acid: Post-Marketing Renal Safety There have been 25 cases of ARF reported to the FDA in patients given Zoledronic acid as of July 29 Zoledronic Acid is not indicated in patients with a creatinine clearance of < 35 ml/min What about Oral bisphosphonates and CKD: Risedronate Miller PD, Roux C, Boonen S, et al. J Bone Miner Res. 25;2: retrospective analysis of data from nine randomized controlled trials that included a total of 8,996 patients Severe renal impairment: CrCl <3 ml/min Moderate renal impairment: CrCL 3 5 ml/min Mild renal impairment: Creatinine clearance (CrCl) 5 8 ml/min Osteonecrosis of the Jaw A confirmed case of bisphosphonate-associated ONJ was defined as an area of exposed bone in the maxillofacial region that did not heal within 8 weeks after identification by a health care provider in a patient who was receiving or had been exposed to a bisphosphonate
9 ONJ Comparative Risks (1) Women age (from Swedish National Bureau of Statistics and database of Olmsted County, MN, USA.) M. Lewiecki 27 Kanis JA et al. Osteoporos Int. 21;12: Pharmcoepidemiol Drug Saf. 23;12: National Center for Health Statistics. JADA. 26;137: Fosamax: Is Long Term Use Linked to Subtrochanteric Femoral Fractures? ABC News Good Morning America March 9, 21 Atypical Fractures of Femoral Shaft Transverse fractures of the femoral shaft Bilateral in 2/3 of patients Delayed healing or non-healing common Prolonged use (> 5 years) of alendronate +/- other anti-resorptive medications Severely suppressed bone turnover?
10 Subtrochanteric Stress Fracture Associated with a Typical Cortical Stress Reaction Kwek E et al. N Engl J Med 28;359: Atypical Fractures of Femoral Diaphysis Visekruna, J Clin Endocrinol Metab 28;93: Copyright 28 The Endocrine Society American Academy of Orthopedic Surgery meeting: March 8, 21 One study compared the bone structure of 61 women with osteoporosis taking bisphosphonates for > 4 years to 5 patients taking calcium and vitamin D supplements. There was an association between prolonged therapy and declining cortical bone structural integrity. The second study, looked at bone samples taken from 21 post-menopausal women treated for femoral fractures. 12 patients had taken bisphosphonates (average of 8.5 yrs) - 9 hadn t been treated with the drugs. Subjects taking bisphosphonates had a reduction in bone tissue heterogeneity compared with women not receiving the drugs
11 Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort Study Analyzed data from 11,944 patients with osteoporosis Atypical subtrochanteric femur fractures had many similar features in common with classical osteoporotic hip fractures, including patient age, gender, and trauma mechanism. The data showed that patients taking bisphosphonates and those not taking bisphosphonates had similar numbers of atypical subtrochanteric femur fractures relative to classical osteoporotic hip fractures Abrahamsen B., Eiken P., Eastell R. J Bone Miner Res. 29 Jun;24(6): Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: Abrahamsen B., Eiken P., Eastell R. J Bone Miner Res. 29 Jun;24(6): Subtrochanteric Fractures: Results from the HORIZON-Recurrent Fracture Trial 2127 men and women with hip fractures Compared baseline characteristics of patients with subtrochanteric femoral fractures and compared them to patients with other types of incident hip fracture Adachi J, et al ASBMR 29
12 Subtrochanteric Fractures: Results from the HORIZON-Recurrent Fracture Trial At baseline, a total of 16/2127 (5.%) patients had sustained subtrochanteric fractures The mean age, age, sex and BMI were similar between groups. Femoral neck and total hip BMD, and distribution of femoral neck BMD were similar between groups. There were no clinically relevant differences in concomitant diseases or medications (glucocorticoids, anticonvulsants or psychoactive drugs) between groups. Adachi J, et al ASBMR 29 Subtrochanteric Fractures: Results from the HORIZON-Recurrent Fracture Trial This post hoc analysis demonstrated that subtrochanteric fractures are not uncommon and do occur in bisphosphonate naive patients, though it failed to show factors that would identify those at greater risk for subtrochanteric fracture Adachi J, et al ASBMR 29 Subtrochanteric Fractures: VA Retrospective Study Reviewed 8, hip fracture classifications in VA system over past 1 years. 9% of all hip fractures were subtrochanteric No difference in incidence between those exposed or never exposed to bisphosphonates Saag et al. ASBMR 29
13 FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures March 1,21 At this point, the data that FDA has reviewed have not shown a clear connection between bisphosphonate use and a risk of atypical subtrochanteric femur fractures. FDA recommends that Patients should: Not stop taking medication unless told to do so by your healthcare professional. Talk to their healthcare professional if they develop new hip or thigh pain, or have any concerns with your medications. Report any side effects with bisphosphonates to FDA's MedWatch program FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures March 1,21 FDA recommends that Healthcare Professionals should: Be aware of the possible risk of atypical subtrochanteric femur fractures in patients taking oral bisphosphonates. Continue to follow the recommendations in the drug label when prescribing oral bisphosphonates. Discuss with patients the known benefits and potential risks with using oral bisphosphonates. Report any adverse events with the use of obisphosphonates to FDA's MedWatch program FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures March 1,21
14 Bisphosphonate Holiday? FLEX: Study Timeline FIT: 3 to 4.5 years Time Between FIT and FLEX 1 to 2 years FLEX: 5 years F F 1 F 2 F 3 F 4 FL FL 1 FL 2 FL 3 FL 4 FL 5 Year F = FIT; FL = FLEX. Ensrud KE et al. J Bone Miner Res. 24;19: Lumbar Spine BMD From Beginning of FIT to Completion of FLEX Mean Percent Change From FIT Baseline, % FIT 3 to 4.5 years Time Between FIT and FLEX 1 to 2 years FLEX 5 years 3.7% P<.1 F F 1 F 2 F 3 F 4 = ALN/placebo (n = 437) Year FL FL 1 FL 2 FL 3 FL 4 FL 5 = ALN/ALN (pooled 5-mg and 1-mg groups: n = 662) F = FIT; FL = FLEX. Black DM et al. JAMA. 26;296:
15 Total Hip BMD Change From Beginning of FIT to Completion of FLEX Mean Percent Change From FIT Baseline, % FIT 3 to 4.5 years Time Between FIT and FLEX 1 to 2 years FLEX 5 years 2.4% P<.1 1 F F 1 F 2 F 3 F 4 = ALN/placebo (n = 437) FL FL 1 FL 2 FL 3 FL 4 FL 5 Year = ALN/ALN (pooled 5-mg and 1-mg groups: n = 662) F = FIT; FL = FLEX. Black DM et al. JAMA. 26;296: Serum CTx: Mean Absolute Value Change From FIT and FLEX Baselines Mean Absolute Value, ng/ml FIT 3 to 4.5 years Time Between FIT and FLEX 1 to 2 years FLEX 5 years. F F 1 F 2 F 3 F 4 FL FL 1 FL 2 FL 3 FL 4 FL 5 = ALN/placebo (n = 97) Year = ALN/ALN (pooled 5-mg and 1-mg groups: n = 139) 56% P<.1 F = FIT; FL = FLEX; CTx = C-telopeptide of type 1 collagen. 1. Black DM et al. JAMA. 26;296: FLEX Incidence of Fractures 25 ALN/PLB (n = 437) ALN/ALN (n = 662) % Fracture Incidence ARR = 2.9% P =.13 RR =.45 CI (.2,.8) RR =.9 CI (.6, 1.2) RR = 1. CI (.8, 1.3) RR = 1. CI (.5, 2.1) 5% 2% 11% 1% 19% 19% Clinical Vertebral Vertebral Morphometric Abbreviations: ALN, alendronate; PLB, placebo. Black DM, et al. JAMA. 26;296: Nonvertebral 3% 3% Hip
16 FLEX: Study Design FIT N = 6,459 Placebo n = 3,223 Alendronate* n = 3,236 Eligible for FLEX screening N = 2,852 FIT (3 4.5 years) Post-FIT (1 2 years) Randomized in FLEX N = 1,99 FLEX (5 years) Placebo N n = 437 Alendronate 5 mg n = 329 Alendronate 1 mg n = 333 * Alendronate 5 mg/day for Years 1 2, then 1 mg/day. 1. Black DM et al. JAMA. 26;296: Pooled When to Consider a Bisphosphonate Holiday When patient never needed treatment in the first place Retrospective application of NOF guide After good BMD response to at least 5 years treatment and fracture risk no longer high No fracture, T-score >-2.5 Continue treatment in high-risk patients Previous fractures, T-score -2.5 and below When to End a Bisphosphonate Holiday Not clear Possible approaches Arbitrarily restart treatment after 1 2 years Monitor BMD/BTM every 6 12 months and restart treatment when significant decrease in BMD or increase in BTM Reconsider treatment plan if fracture or change in clinical status
17 New FDA-approvals for Glucocorticoidinduced Osteoporosis Alendronate Risedronate Zoledronic Acid Teriparatide Zoledronic Acid in GIOP Prevention Subpopulation Risedronate Zoledronic acid Lumbar Spine 1 Femoral Neck 1 Total Hip 2 % Change From Baseline * * 6 12 Time (months) * 6 12 Time (months) * * 6 12 Time (months) Graphs present least squares means and 95% confidence intervals. *P <.5, between treatment comparisons; P <.1, between treatment comparisons. 1. Reid DM, et al. Lancet. 29 Zoledronic acid in GIOP Treatment Subpopulation Risedronate Zoledronic acid Lumbar Spine 1 Femoral Neck 1 Total Hip 2 % Change From Baseline * * 6 12 Time (months) * 6 12 Time (months) * * 6 12 Time (months) Graphs present least squares means and 95% confidence intervals. *P <.5, between treatment comparisons. 1. Reid DM, et al. Lancet. 29
18 Teriparatide Versus Alendronate for Treatment of Glucocorticoid-induced Osteoporosis: 36-month Results KG Saag 1, JR Zanchetta 2, JP Devogelaer 3, R Adler 4,K See 5,GP Dalsky 5, K Krohn 5, JH Krege 5, MR Warner 5 Arthritis and Rheumatism 29 Study Design Screening Phase 18-month Primary Phase 18-month Continuation Phase All Subjects Teriparatide 2 μg/day + oral placebo Alendronate 1 mg/day + placebo injection Teriparatide 2 μg/day + oral placebo Alendronate 1 mg/day + placebo injection Calcium and vitamin D Calcium and vitamin D Visit -1.5 to Mont mo mo 24 mo 3 mo 36 mo h mo mo Randomizatio n End of End of Baseline Assessments Primary Phase Continuation Phase Saag et al. Arthritis and Rheumatism 29 Percent Change in BMD Mean ± SE Lumbar Spine BMD * 8.% 3.8% Teriparatide Endpoint Months Alendronate n= Teriparatide n= % 5.2% Alendronate 11.% 5.3% 8.9% 4.2% * P<.5; P<.1 Teriparatide vs. Alendronate BMD = bone mineral density, g/cm 2
19 Proximal Femur BMD Percent Change in BMD Mean ± SE 1 Femoral neck Percent Change in BMD Mean + SE 1 Total hip Teriparatide 8 8 Teriparatide 6 6 * 6.3% 5.1% % 4.4% * 2 3.4% 2.6% 2 2.7% 2.2% Alendronate Alendronate 36 Endpoint 36 Endpoint Months Months 145 ALN n= ALN n= TPTD n= TPTD n= Saag et al. Arthritis and Rheumatism 29 *P<.5, P<.1, P<.1 Teriparatide vs. Alendronate Number of Patients With New Vertebral Fractures Alendronate (n=169)* Teriparatide (n=173)* P-value Vertebral radiographic 13 (7.7%) 3 (1.7%).7 Clinical vertebral** 4 (2.4%).37 Mild 7 (4.1%) 1 (.6%).26 Moderate Severe 2 (1.2%) 4 (2.4%) 2 (1.2%) Saag et al. Arthritis and Rheumatism American College of Rheumatology Guidelines for Glucocorticoid-induced Osteoporosis Will include Zoledronic Acid as well as Teriparatide as treatment options Will incorporate Clinical Risks for Fracture as well as T-scores (similar to FRAX) to stratify low versus high risk patients
20 RANK-RANKL-OPG Pathway OPG RANKL RANK Denosumab Growth factors Hormones Cytokines RANKL OPG CFU-M Prefusion osteoclast Multinucleated osteoclast Osteoclast Stromal cells Osteoblast BONE Adapted from Boyle et al. Nature. 23;423:337. CFU-M = colony-forming unit macrophage. Denosumab for Postmenopausal Osteoporosis: FREEDOM Study BMD Lumbar spine 9.2% (P <.1) Total hip 6.% (P <.1) BTMs CTX 72% (P <.1) Fracture risk Vertebral 68% (P <.1) Hip 4% ( P =.36) Nonvertebral 2% ( P =.11) Cummings SR, et al. N Engl J Med. 29;361: FREEDOM trial: Adverse Events Adverse Events Denosumab Placebo All 92.8% 93.1% Infections 52.9% 54.4% Cancer 4.8% 4.3% Hypocalcemia %.1% ONJ % % Cummings SR, et al. N Engl J Med. 29;361:
21 FREEDOM Trial: Serious Adverse Events SAEs Denosumab Placebo All 25.8% 25.1% Infections 4.1% 3.4% Cancer 3.7% 3.2% Atrial fibrillation.7%.7% Deaths 1.8% 2.3% Cardiovascular events 4.8% 4.6% Abbreviation: SAEs, serious adverse events. With permission from Cummings SR, et al. N Engl J Med. 29;361: Emerging Therapies Antiresorptive (anti-catabolic) Denosumab Lasofoxifene Bazedoxifene CE/bazedoxifene Odanacatib New delivery systems Osteo-anabolic (bone-forming) Sclerostin inhibitor Variations of parathyroid hormone Calcium-sensing receptor antagonist (calcilytic) New delivery systems Combinations of antiresorptive and anabolic Resorbing Osteoclast
22 Signals Determining Differentiation Toward Osteoblasts and Acting on Mature Osteoblasts to Enhance Bone Formation Preosteoblast Wnt and BMP PTH Osteoblast Under the influence of Wnt and BMP, undifferentiated mesenchymal cells differentiate toward cells of the osteoblast lineage. Bone Formation New Bone Abbreviations: BMP, bone morphogenic protein; PTH, parathyroid hormone. Wnt Antagonists LRP5 and LRP6 Sclerostin DKK-1 Cell Membrane Kremen Frizzled Wnt sfrp-1 Axin APC GSK3ß ß-Catenin Proteosome Cytoplasm Nucleus The extracellular Wnt antagonists prevent Wnt signaling. Dikkopf-1 (Dkk-1) in association with Kremen and sclerostin bind LRP5 and LRP6.
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Honoraria: Amgen, Merck, Shire Consulting : AbbVie, Amgen, Merck,
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationOSTEONECROSI DEI MASCELLARI (ONJ): PREVENZIONE, DIAGNOSI, TRATTAMENTO UPDATE 2010
OSTEONECROSI DEI MASCELLARI (ONJ): PREVENZIONE, DIAGNOSI, TRATTAMENTO UPDATE 2010 Alessandria, 5 giugno 2010 Novità nel trattamento dell osteoporosi Stefania Boldini Francesco Bertoldo Dipartimento di
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationAACE. Orlando Drug Holidays. Disclosures. Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health
AACE Orlando 2016 Drug Holidays Disclosures Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health Scientific grants: Alexion, Amgen, Immunodiagnostics, Lilly, Merck, Regeneron, Radius Health, Roche
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationTREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE. Nelson B. Watts, MD
TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO Honoraria: Amgen, Radius, Shire Consulting
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationNew Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence
New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence John P. Bilezikian, MD, PhD(hon), MACE Silberberg Professor of Medicine Vice-Chair for International
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationDisclosures D. Black. Bisphosphonates: Background, Efficacy and Recent Controversies. Page 1. Research Funding: Novartis, Merck
Bisphosphonates: Background, Efficacy and Recent Controversies Disclosures D. Black Research Funding: Novartis, Merck Dennis M. Black, PhD Consulting: Amgen, Lilly, Zosano, Nycomed Dept. of Epidemiology
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationOsteoporosis in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Osteoporosis in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
More informationCalcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!!
Calcium, Vitamin D and Bisphosphonates: Benefits, Risks and Drug Holiday Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Lilly, Merck, Novartis Research grants:
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationNAMS Practice Pearl. Use of Drug Holidays in Women Taking Bisphosphonates. Released April 1, 2013
NAMS Practice Pearl Use of Drug Holidays in Women Taking Bisphosphonates Released April 1, 2013 Dima L. Diab, MD 1, and Nelson B. Watts, MD 2 ( 1 Cincinnati VA Medical Center, Cincinnati, OH, 2 Mercy Health
More informationHow long to treat? Disclosure. What is the real problem? Conclusions
Disclosure How long to treat? 11 th Annual Update on Osteoporosis and Skeletal Health Institutional Grant / Research Support Amgen, Eli Lilly, Merck Consulting / Speaking Amgen, Eli Lilly, Merck, Radius
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 ACTONEL 5 mg, film-coated tablet B/14 (CIP code: 354 362-3) ACTONEL 30 mg, film-coated tablet B/28 (CIP
More informationRefracture Prevention The Role of Primary Care
MonashHealth Refracture Prevention The Role of Primary Care Professor Peter R Ebeling AO MBBS MD FRACP Head, Department of Medicine School for Clinical Sciences Monash Health Translation Precinct Monash
More informationBisphosphonate treatment break
Bulletin 110 December 2015 Bisphosphonate treatment break Bisphosphonates have been widely used in the treatment of osteoporosis with robust data demonstrating efficacy in fracture risk reduction over
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationDrugs Approved for Prevention and Treatment of Postmenopausal Osteoporosis
Other Treatments of Osteoporosis- Who Should Get Bisphosphonates David Slovik, M.D. Endocrine Unit Newton-Wellesley Hospital Massachusetts General Hospital Harvard Medical School Massachusetts Medical
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationAtypical Femoral Fractures Insights and Enigmas
Atypical Femoral Fractures Insights and Enigmas Madhu Mehta, M.D. Clinical Asst. Prof. of Medicine Department of Immunology/Rheumatology The Ohio State University Abreviations used TFF- Typical femoral
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More information7/5/2016. We need drugs that. Disclosures. New Osteoporosis Treatments. What we have today. Maintain or promote bone formation
New Osteoporosis Treatments Disclosures Mary L. Bouxsein, PhD Department of Orthopedic Surgery Harvard Medical School, Boston, MA Advisory Board: Research funding: Merck, Eli Lilly, Radius Merck, Amgen
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationRenata Caudarella. Fondazione Ettore Sansavini per la Ricerca Scientifica (Health Science Foundation ) - GVM Care & Research
Renata Caudarella Fondazione Ettore Sansavini per la Ricerca Scientifica (Health Science Foundation ) - GVM Care & Research Introduc/on During the past two decades, many randomized controlled trials (RCTs)
More informationHow to treat osteoporosis With what and for how long?
How to treat osteoporosis With what and for how long? Professor Neil Gittoes Consultant Endocrinologist & Honorary Professor Where will we be going? Drug therapies Current Indications Contraindications/unmet
More informationUpcoming Agents for Osteoporosis
Upcoming Agents for Osteoporosis May 5, 2017 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Professorial Fellow, Institute of Health and Ageing Australian Catholic
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationAACE. Osteoporosis Treatment: Then and Now
AACE 25 th Annual Scientific and Clinical Congress Osteoporosis Treatment: Then and Now Orlando, FL May 28, 2016 Michael R. McClung, MD Oregon Osteoporosis Center Portland, Oregon, USA Disclosures I am
More informationA KL/R / AN A K/O / P O G G
Outline and New Treatments on the Horizon Steven R. Cummings, MD CPMC and UCSF San Francisco Coordinating Center Support from Lilly and Amgen New treatments, new mechanisms of action Cathepsin K inhibition
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationRheumatology. keeping Joints in Motion. Treating and Preventing Fractures
Rheumatology keeping Joints in Motion Treating and Preventing Fractures Robin K. Dore, MD Clinical Professor of Medicine David Geffen School of Medicine at UCLA, Los Angeles CA Private practice, Tustin
More informationAN OVERVIEW of TREATMENT: WHO and WHEN to TREAT
AN OVERVIEW of TREATMENT: WHO and WHEN to TREAT Dolores Shoback, MD Professor of Medicine, UCSF San Francisco VA Medical Center July 16, 21 ~ QUESTIONS ~ Who should receive therapy to prevent fractures?
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationTherapeutic Updates in the Prevention and Treatment of Osteoporosis
Therapeutic Updates in the Prevention and Treatment of Osteoporosis 2013 Fall Managed Care Forum Las Vegas November 15, 2013 Steven T Harris MD FACP Clinical Professor of Medicine University of California,
More informationACP Colorado-Evidence Based Management of Osteoporosis
ACP Colorado-Evidence Based Management of Osteoporosis Micol S. Rothman, MD Associate Professor of Medicine and Radiology Clinical Director Metabolic Bone Program University of Colorado School of Medicine
More information11/4/2018. Osteoporosis Update. ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East. No disclosures.
Osteoporosis Update ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East No disclosures. 1 Goals Review screening recommendations and workup of secondary causes
More informationOsteoporosis Management in Older Adults
Osteoporosis Management in Older Adults Angela M Cheung, MD, PhD, FRCPC, CCD Professor of Medicine, University of Toronto Disclosures Relationship with Commercial Entities: Honoraria from: Amgen, Eli Lilly,
More informationFracture=Bone Attack:
Fracture=Bone Attack: Linking Hip Fractures to Osteoporosis Care Angela M. Cheung, MD, PhD, FRCPC Professor of Medicine, University of Toronto Potential Conflicts of Interests Industry Grants (to UHN)
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationNEW HORIZONS IN OSTEOPOROSIS THERAPY. Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN
NEW HORIZONS IN OSTEOPOROSIS THERAPY Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN DISCLOSURES SUNDEEP KHOSLA, M.D. Investigator-initiated grant Merck No non-fda approved recommendations RISK ASSESSMENT
More information9/9/2015 OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY DISCLOSURES
OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Stock options/holdings,
More informationTask Force Co-Chairs. Members
Managing Osteoporosis Patients After Long-Term Bisphosphonate Treatment Report of a Task Force* of the American Society for Bone and Mineral Research Robert A. Adler, MD Task Force Co-Chairs Ghada El-Hajj
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 DIDRONEL 200 mg, tablets B/60 (CIP code: 345 098-5) DIDRONEL 400 mg, tablets B/14 (CIP code: 333
More informationConflict of Interest Jonathan D. Adachi
Conflict of Interest Jonathan D. Adachi Consultant/Speaker Actavis Amgen Eli Lilly Merck Clinical Trials Amgen Eli Lilly Merck Novartis Stock None to declare Current Controversies In Osteoporosis Provided
More informationClinical Specialist Statement Template
Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can
More informationHRT and Risedronate Combined Anabolic and Antiresorptive Therapy
Optimizing Combined and Sequential Osteoanabolic and Antiresorptive Therapy Benjamin Leder, M.D. Endocrine Unit Massachusetts General Hospital Boston, MA Antiresorptive and Osteoanabolic Therapies Increase
More informationReducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians. Please complete the preassessment before the session starts.
Reducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians Please complete the preassessment before the session starts. Sponsorship and Support This educational activity is jointly
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationOsteoporosis for the PCP and consultant COPYRIGHT. Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center
Osteoporosis for the PCP and consultant Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center Beth Israel Deaconess Medical Center Potential conflicts of interest None GOALS When to screen/treat?
More informationHot Topics in Osteoporosis and Fracture Prevention
Hot Topics in Osteoporosis and Fracture Prevention Sid Feldman, MD CCFP (COE) FCFP Sandra Kim, MD, FRCPC November 15, 2018 Family Medicine Forum, Toronto Faculty/Presenter Disclosure Faculty: Sid Feldman
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationA Review of Bone Health Issues in Oncology
A Review of Bone Health Issues in Oncology David L. Kendler MD FRCPC CCD Professor of Medicine (Endocrinology) University of British Columbia Vancouver Canada Disclosures David Kendler has received research
More informationArizona Chapter AACE Paul D. Miller, M.D.
Arizona Chapter AACE Paul D. Miller, M.D. Management of fractures in CKD and atypical subtrochanteric femur fractures September 2018 Paul D. Miller, M.D. Disclosures: Amgen (Consultant, Advisory Board,
More informationMedicine and the Current Correlation Between Fosamax and Fractures
Medicine and the Current Correlation Between Fosamax and Fractures American Association for Justice Fosamax Telseminar June 22, 2011 2:00 3:30 pm EDT By: William B. Curtis Michael S. Wilson Curtis Law
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More information